Victoria Johnson

Researchers compared Neuro-QoL scores between patients treated with natalizumab and ocrelizumab, another high-efficacy treatment for MS.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee discussed issues in caring for patients with OSA.

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.

Researchers from the University of Utah analyzed the use of their telestroke system with 27 outside “stroke” facilities.

Researchers analyzed disparities in stroke rehab and found that women and African Americans had the lowest functional performance.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions.

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.

Kimberly Allen-Philbey, a PhD candidate at the Barts MS Center in London, discussed the advantages of using a personalized dosing schedule of off-label, subcutaneous cladribine.

Researchers analyzed data from the 10,472 Medicare beneficiaries diagnosed with mild cognitive impairment or dementia in California.

Jemima Akinsanya, DO, Neuroimmunology Clinical Fellow at the National Institutes of Health, discussed new studies of anakinra and tolebrutinib in MS.

Ilena George, MD, of Massachusetts General Hospital, discussed a cohort of patients with early DMT prescription and low rates of clinical conversion.

Researchers used patient, family, and public engagement to develop a 14-item DMD-QoL questionnaire.

Researchers collected data from 457 stroke centers in 70 countries encompassing 6 continents, which included more than 80,000 stroke hospitalizations.

Yujie Wang, MD, a neurologist from the University of Washington Medical Center, discussed examining the 1-hour post monitoring period of natalizumab infusion amid the COVID-19 pandemic.

Researchers studied associations between CSF neurofilament light, neurogranin, and t-tau with measures of cortical thickness, white matter hyperintensities, and microstructural integrity.

Researchers found significant differences between clinically relevant areas in participants with progressive MS, relapsing MS, and healthy controls.

Stephanie Blandford, MSc, a PhD candidate at Memorial University of Newfoundland, discussed some advantages of using IL-1RA over NfL in predicting disability in multiple sclerosis.

Researchers studied concentrations of recombinant tissue plasminogen activator locally and systemically in patients with IS.

Researchers found a 70% infarct resolution and 90% motor recovery in mice injected with the EFF-nanotransfected cells.

Researchers found improvements in SIB and NPI score between high-dose and placebo groups.

Researchers on the FDA’s advisory committee conducted a review of the studies and evidence ahead of the treatment’s PDUFA date on June 7, 2021.

An update on the phase 1b study of Pfizer’s investigational DMD treatment was presented at the MDA 2021 conference.

Researchers conducted a post-hoc analysis of Study 19 to determine hazard ratios of milestone occurrences in amyotrophic lateral sclerosis.

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.

Researchers studied associations between obstructive sleep apnea and varied markers of adiposity.

Researchers found that taking into account PWA increased total arousal index more than 3-fold.

Researchers conducted a systematic review of studies reporting on patients with both COVID-19 and stroke and found worse outcomes compared to patients with stroke alone.

Researchers analyzed levels of sGFAP in participants from the N-MOmentum study that assessed inebilizumab (Uplizna; Viela Bio) in relapsing-remitting MS.